Physician profile
Sunil Gupta
NPI 1235158031
$14,510.25
in general payments reported to CMS, 2019-2025
41 companies · $2,520 in 2025
The $2,520 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $1,644 · 2021: $1,959 · 2022: $2,315 · 2023: $1,912 · 2024: $2,859 · 2025: $2,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,290.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,908.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,266.28 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $777.98 | 2019-2025 | Entyvio, Eohilia |
| Astrazeneca Pharmaceuticals LP | $619.38 | 2023-2025 | Airsupra, Tezspire |
| Pfizer INC. | $579.15 | 2019-2025 | |
| Madrigal Pharmaceuticals | $516.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $490.85 | 2019-2024 | Clenpiq, Rebyota |
| Celgene Corporation | $465.87 | 2021-2024 | Zeposia |
| Allergan, INC. | $409.77 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $365.03 | 2020-2023 | |
| Ardelyx, INC. | $338.66 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $332.14 | 2022-2025 | |
| Novo Nordisk INC | $323.08 | 2020-2025 | Wegovy |
| Gilead Sciences, INC. | $263.00 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $232.73 | 2024-2025 | Zenpep |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $231.58 | 2020-2023 | Dificid |
| Braintree Laboratories, INC. | $225.87 | 2019-2023 | Sutab, Suflave |
| Janssen Scientific Affairs, LLC | $198.91 | 2022-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $193.45 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $192.94 | 2019-2024 | Linzess |
| Abbott Laboratories | $187.79 | 2019-2020 | |
| Redhill Biopharma INC. | $185.20 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $132.93 | 2024 | |
| Alfasigma USA, INC. | $129.93 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Amarin Pharma, INC. | $124.82 | 2019 | |
| Lilly USA, LLC | $108.78 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $102.61 | 2025 | Dupixent |
| Janssen Biotech, INC. | $88.76 | 2024-2025 | Tremfya, Simponi, Stelara |
| Intercept Pharmaceuticals, INC. | $81.72 | 2020-2025 | |
| Qol Medical, LLC | $55.28 | 2022-2025 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.19 | 2023-2024 | Cyltezo |
| Amgen INC. | $35.68 | 2023 | Amjevita, Avsola |
| Endo Pharmaceuticals INC. | $30.21 | 2020 | |
| Celltrion USA INC. | $24.29 | 2024 | Vegzelma |
| Galderma Laboratories, L.P. | $22.07 | 2023 | Dysport |
| Capsovision, INC. | $21.24 | 2024 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $20.69 | 2024 | Xarelto |
| Lucid Diagnostics INC. | $19.47 | 2022 | |
| Medtronic, INC. | $18.04 | 2023 | Gi Genius |
| Romark Laboratories, Lc | $16.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.